Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POG-9705: Combination Chemotherapy for Better Risk ALL
NCT00003671Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Dec 1998
- Primary completion
- Nov 2002
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Replacement Enzymes
- Countries
- 5
01
Overview
A Phase 2 trial of asparaginase escherichia coli, cyclophosphamide, cytarabine, daunorubicin, dexamethasone in acute lymphoblastic leukemia (ALL), sponsored by Children's Oncology Group. Started Dec 1998; status: completed.
02
Drugs
asparaginase escherichia colicyclophosphamidecytarabinedaunorubicindexamethasone
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00003671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003671.